Galderma Launches 'Wake Up To Restylane' Campaign Targeting Natural Beauty Demand
Event summary
- Galderma launched the 'Wake Up To Restylane' global campaign on January 29, 2026, positioning Restylane as an everyday beauty ally.
- The campaign was unveiled at the IMCAS World Congress 2026 in Paris, alongside new clinical data reinforcing Restylane’s efficacy across key facial areas and décolletage.
- Galderma’s research of over 4,300 consumers and healthcare professionals across four countries highlights HA treatments as a top injectable choice ahead of neuromodulators.
- Restylane has administered over 77 million treatments worldwide, with a portfolio designed for diverse patient needs across facial areas.
The big picture
Galderma’s 'Wake Up To Restylane' campaign aligns with the broader industry shift towards minimally invasive, natural-looking aesthetic treatments. The focus on personalized results and everyday beauty resonates with consumers seeking self-care solutions that fit seamlessly into their lifestyles. With over 77 million treatments administered, Restylane remains a key player in the dermatology market, addressing trends such as menopause-related skin health and medication-driven weight loss.
What we're watching
- Market Positioning
- How Galderma will differentiate Restylane in a competitive HA treatment market, especially among new-to-injectables consumers.
- Clinical Innovation
- The pace at which Galderma can sustain clinical data support for Restylane’s versatility across facial areas and skin concerns.
- Consumer Trends
- Whether the campaign will successfully tap into the growing demand for effortless, natural-looking beauty solutions.